EMA
guidance
· 2024-01-12
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2024
Summary
PRAC highlights potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines and recommends precautionary measures.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures